4.5 Review

Patient- and Tumour-related Prognostic Factors for Urinary Incontinence After Radical Prostatectomy for Nonmetastatic Prostate Cancer: A Systematic Review and Meta-analysis

期刊

EUROPEAN UROLOGY FOCUS
卷 8, 期 3, 页码 674-689

出版社

ELSEVIER
DOI: 10.1016/j.euf.2021.04.020

关键词

Systematic review; Evidence synthesis; Prostate cancer; Urinary incontinence; Prognostic factors; Patient-related factors; Tumour-related factors

资金

  1. Janssen
  2. IPSEN
  3. European Association of Urology
  4. Bayer
  5. Astellas
  6. Cancer Australia
  7. Cancer Research UK
  8. Medical Research Council
  9. National Institute of Health
  10. Pierre Fabre Oncologie
  11. Amgen
  12. AstraZeneca
  13. Bristol-Myers Squibb
  14. Celgene
  15. Dendreon
  16. Ferring
  17. GSK
  18. Incyte
  19. Janssen Cilag
  20. Merck
  21. MSD
  22. Novartis
  23. Pfizer
  24. Roche
  25. Sanofi Aventis
  26. SeaGen
  27. Shionogi
  28. Synthon
  29. Takeda
  30. Teva/OncoGenex
  31. Sanofi

向作者/读者索取更多资源

This study systematically reviewed patient- and tumor-related prognostic factors for post-radical prostatectomy urinary incontinence (UI). The results showed that increasing age, shorter length of the membranous urethra, greater prostate volume, and higher Charlson comorbidity index were independent prognostic factors for UI within 3 months after radical prostatectomy. These factors remained predictive at 3-12 months post-surgery.
Context: While urinary incontinence (UI) commonly occurs after radical prostatectomy (RP), it is unclear what factors increase the risk of UI development.Objective: To perform a systematic review of patient-and tumour-related prognostic factors for post-RP UI. The primary outcome was UI within 3 mo after RP. Secondary outcomes included UI at 3-12 mo and >12 mo after RP.Evidence acquisition: Databases including Medline, EMBASE, and CENTRAL were searched between January 1990 and May 2020. All studies reporting patient-and tumour-related prognostic factors in univariable or multivariable analyses were included. Surgical factors were excluded. Risk of bias (RoB) and confounding assess-ments were performed using the Quality In Prognosis Studies (QUIPS) tool. Random -effects meta-analyses were performed for all prognostic factor, where possible. Evidence synthesis: A total of 119 studies (5 randomised controlled trials, 24 prospective, 88 retrospective, and 2 case-control studies) with 131 379 patients were included. RoB was high for study participation and confounding; moderate to high for statistical analysis, study attrition, and prognostic factor measurement; and low for outcome measurements. Significant prognostic factors for postoperative UI within 3 mo after RP were age (odds ratio [OR] per yearly increase 1.04, 95% confidence interval [CI] 1.03- 1.05), membranous urethral length (MUL; OR per 1-mm increase 0.81, 95% CI 0.74-0.88), prostate volume (PV; OR per 1-ml increase 1.005, 95% CI 1.000-1.011), and Charlson comorbidity index (CCI; OR 1.28, 95% CI 1.09-1.50).Conclusions: Increasing age, shorter MUL, greater PV, and higher CCI are independent prognostic factors for UI within 3 mo after RP, with all except CCI remaining prognostic at 3-12 mo. Patient summary: We reviewed the literature to identify patient and disease factors associated with urinary incontinence after surgery for prostate cancer. We found increasing age, larger prostate volume, shorter length of a section of the urethra (membranous urethra), and lower fitness were associated with worse urinary inconti-nence for the first 3 mo after surgery, with all except lower fitness remaining predictive at 3-12 mo. (c) 2021 European Association of Urology. Published by Elsevier B.V. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据